Movement Alert｜Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound

Market Focus07-20

On July 20, Kelun-Biotech rose 3.41% in regular trading, trading at HK$514.0/share, with turnover of approximately HK$102 million. The rebound was driven by multiple investment banks raising their target prices and a broad recovery across the biotech sector.

On the news front, JPMorgan raised its target price from HK$535 to HK$648, maintaining an Overweight rating, citing significantly reduced clinical risk following the successful OptiTROP-Lung06 Phase III trial. Goldman Sachs also raised its target to HK$582.95, maintaining a Buy rating, and increased the probability of success for the Lung06 study from 81% to 90%. The stock had previously pulled back for two consecutive sessions following a clinical data-driven 11% surge on July 15, when its TROP2 ADC sac-TMT combined with Keytruda met the primary endpoint in first-line PD-L1-negative NSCLC treatment.

Sector-wide, biotech stocks rallied collectively, with Remegen up 5.84%, Akeso up 3.68%, BeiGene up 3.56%, 3SBio up 3.28%, and Innovent Bio up 3.15%, reflecting improved market sentiment supporting the stock's stabilization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199244198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199244198","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound","media":"Market Focus","content":"<p><p>On July 20, Kelun-Biotech rose 3.41% in regular trading, trading at HK$514.0/share, with turnover of approximately HK$102 million. The rebound was driven by multiple investment banks raising their target prices and a broad recovery across the biotech sector.</p><p>On the news front, JPMorgan raised its target price from HK$535 to HK$648, maintaining an Overweight rating, citing significantly reduced clinical risk following the successful OptiTROP-Lung06 Phase III trial. Goldman Sachs also raised its target to HK$582.95, maintaining a Buy rating, and increased the probability of success for the Lung06 study from 81% to 90%. The stock had previously pulled back for two consecutive sessions following a clinical data-driven 11% surge on July 15, when its TROP2 ADC sac-TMT combined with Keytruda met the primary endpoint in first-line PD-L1-negative NSCLC treatment.</p><p>Sector-wide, biotech stocks rallied collectively, with Remegen up 5.84%, Akeso up 3.68%, BeiGene up 3.56%, 3SBio up 3.28%, and Innovent Bio up 3.15%, reflecting improved market sentiment supporting the stock's stabilization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 09:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Kelun-Biotech rose 3.41% in regular trading, trading at HK$514.0/share, with turnover of approximately HK$102 million. The rebound was driven by multiple investment banks raising their target prices and a broad recovery across the biotech sector.</p><p>On the news front, JPMorgan raised its target price from HK$535 to HK$648, maintaining an Overweight rating, citing significantly reduced clinical risk following the successful OptiTROP-Lung06 Phase III trial. Goldman Sachs also raised its target to HK$582.95, maintaining a Buy rating, and increased the probability of success for the Lung06 study from 81% to 90%. The stock had previously pulled back for two consecutive sessions following a clinical data-driven 11% surge on July 15, when its TROP2 ADC sac-TMT combined with Keytruda met the primary endpoint in first-line PD-L1-negative NSCLC treatment.</p><p>Sector-wide, biotech stocks rallied collectively, with Remegen up 5.84%, Akeso up 3.68%, BeiGene up 3.56%, 3SBio up 3.28%, and Innovent Bio up 3.15%, reflecting improved market sentiment supporting the stock's stabilization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1199244198","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199244198","pubTimestamp":1784511902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Kelun-Biotech rose 3.41% in regular trading, trading at HK$514.0/share, with turnover of approximately HK$102 million. The rebound was driven by multiple investment banks raising their...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|科伦生物常规交易上涨3.41%，生物科技板块反弹，多家银行上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On July 20, Kelun-Biotech rose 3.41% in regular trading, trading at HK$514.0/share, with turnover of approximately HK$102 million. The rebound was driven by multiple investment banks raising their target prices and a broad recovery across the biotech sector.On the news front, JPMorgan raised its target price from HK$535 to HK$648, maintaining an Overweight rating, citing significantly reduced clinical risk following the successful OptiTROP-Lung06 Phase III trial. Goldman Sachs also raised its target to HK$582.95, maintaining a Buy rating, and increased the probability of success for the Lung06 study from 81% to 90%. The stock had previously pulled back for two consecutive sessions following a clinical data-driven 11% surge on July 15, when its TROP2 ADC sac-TMT combined with Keytruda met the primary endpoint in first-line PD-L1-negative NSCLC treatment.Sector-wide, biotech stocks rallied collectively, with Remegen up 5.84%, Akeso up 3.68%, BeiGene up 3.56%, 3SBio up 3.28%, and Innovent Bio up 3.15%, reflecting improved market sentiment supporting the stock's stabilization.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199244198","isCrawlerRequest":true}